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Abstract: The branch chain amino acid leucine is a potent stimulator of protein synthesis in skeletal
muscle. Leucine rapidly enters the cell via the L-Type Amino Acid Transporter 1 (LAT1); however,
little is known regarding the localisation and distribution of this transporter in human skeletal
muscle. Therefore, we applied immunofluorescence staining approaches to visualise LAT1 in wild
type (WT) and LAT1 muscle-specific knockout (mKO) mice, in addition to basal human skeletal
muscle samples. LAT1 positive staining was visually greater in WT muscles compared to mKO
muscle. In human skeletal muscle, positive LAT1 staining was noted close to the sarcolemmal
membrane (dystrophin positive staining), with a greater staining intensity for LAT1 observed in
the sarcoplasmic regions of type II fibres (those not stained positively for myosin heavy-chain 1,
Type II—25.07 ± 5.93, Type I—13.71 ± 1.98, p < 0.01), suggesting a greater abundance of this protein
in these fibres. Finally, we observed association with LAT1 and endothelial nitric oxide synthase
(eNOS), suggesting LAT1 association close to the microvasculature. This is the first study to visualise
the distribution and localisation of LAT1 in human skeletal muscle. As such, this approach provides
a validated experimental platform to study the role and regulation of LAT1 in human skeletal muscle
in response to various physiological and pathophysiological models.
Keywords: LAT1; leucine; protein; amino acid transport
1. Introduction
Amino acid transport is an essential component in the survival of all cells [1], providing substrates
for processes such as protein synthesis [2,3] and cell division [4]. Amino acid transport into cells is of
particular importance within skeletal muscle to maintain positive protein balance [2,3]. Some evidence
suggests that amino acid transporter proteins may also act as receptors, converting extracellular amino
acid abundance into intracellular signals [5–7], a role termed ‘transceptor’ [8].
Of the amino acid transporters identified in skeletal muscle, the L-Type amino acid transporter
1 (LAT1) also known as the solute carrier family 7 member 5 (SLC7A5) has received significant
attention [9–15] due to its role in the ingress of amino acids, vital for optimal stimulation of
muscle protein synthesis (MPS) [16–18]. LAT1 transports leucine (or other branched chain amino
acids (BCAAs)) into the cell via a bi-transport system that simultaneously exports glutamine [19].
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The increase in intracellular leucine/BCAAs subsequently activates the mechanistic target of rapamycin
(mTOR) complex 1 (mTORC1), resulting in an elevation in MPS [20]. Leucine’s reported potency
toward mTORC1 in skeletal muscle [16] is modulated primarily through LAT1, as this is the main
transporter by which leucine moves into cells [9]. Other L-type amino acid transporters are expressed
in skeletal muscle, including LAT2 and LAT4 [21,22]; however, it seems that LAT1 is the primary BCAA
transporter. In LAT1 muscle-specific knockout (mKO) mice, a compensatory increase in SLC7A8/LAT2
mRNA was reported [14], yet a significant reduction in amino acid transport into muscle was apparent,
suggesting that LAT1 is integral to this process. Furthermore, LAT4 is only weakly expressed in skeletal
muscle [21] and is believed to be primarily required in placenta as this transporter functions to deliver
amino acids from the mother to the foetus [23]. Due to its apparent importance to amino acid transport
in skeletal muscle, understanding the role and regulation of LAT1 is essential for studies aimed at
maximising the delivery of dietary protein and amino acids in the context of post-exercise recovery.
Gene expression and protein content of LAT1 are positively associated with mTORC1 activity;
however, increases in LAT1 expression are abolished by the administration of rapamycin, suggesting
that mTORC1 may also regulate LAT1 activity [24]. In human skeletal muscle, essential AA (EAA)
consumption elicits an early increase in LAT1 gene expression followed by elevations in protein
content [12]. Furthermore, these transient effects have also been reported in response to resistance
exercise alone [11], and in combination with EAA consumption [10]. Such data suggest that anabolic
stimuli may initiate signalling pathways, which upregulate both LAT1 gene expression and protein
levels in human skeletal muscle, possibly translating to greater leucine/BCAA transport and a superior
protein synthetic response [2,3,16,25]. However, it is difficult to reconcile the physiological relevance
of changes in LAT1 gene and protein content with LAT1 activity since LAT1 is only active when at
the plasma membrane [9,26]. Therefore, any measure of protein or gene expression in whole muscle
homogenates [10–12] may not allow reliable conclusions to be drawn. To date, the localisation of LAT1
in human muscle is unknown and requires investigation.
Therefore, the aim of the present study was develop and validate immunofluorescent approaches
to study LAT1 cellular distribution and localisation in human skeletal muscle. We hypothesised that,
in basal human skeletal muscle, LAT1 would be located at the plasma membrane and would be
ubiquitously expressed across fibre types.
2. Materials and Methods
2.1. Mouse Skeletal Muscle Sample Collection and Preparation
LAT1 mKO mice were provided as a gift by Dr. Peter Taylor of the University of Dundee. Methods
of generation of this mouse strain have been previously described [14]. Mice (n = 2 mKO, n = 2 wild
type (WT)) were housed in a climate-controlled facility at the University of California Davis, in a
standard 12 h light/dark cycle and fed standard chow ad libitum. All procedures were approved by
the UC Davis Institutional Animal Care and Use Committee (IACUC) and performed under protocol
number 19244. At three months of age, mice were fasted for 5 h before the extensor digitorum longus
(EDL) muscle was surgically removed under anaesthetic (2.5% isofluorane), pinned to cork and frozen
in liquid nitrogen-cooled isopentane. Muscles were subsequently stored at −80 ◦C until sectioned.
Prior to sectioning, the belly of the EDL was blocked in Tissue-Tek Optimal Cutting Temperature (OCT)
Compound (VWR International, Leicestershire, UK) and frozen in liquid nitrogen-cooled isopentane,
at which point the sample was ready for cryo-sectioning. During staining protocols, both WT and mKO
samples were processed and stained simultaneously, and image capture paradigms were also identical.
2.2. Human Skeletal Muscle Sample Collection and Preparation
Ethical approval for the collection of muscle samples was granted by the NHS West Midlands
Black Country Research Ethics Committee (14/WM/0088 and 15/WM/0003), the Hamilton Health
Sciences Research Ethics Board (12-631), and the University of Guelph Research Ethics Board (120C018).
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The study conformed to the standards presented by the Declaration of Helsinki (seventh version).
Written informed consent was obtained from all participants before samples were collected. Muscle
samples for immunofluorescence were obtained from the vastus lateralis muscle of 6 young, healthy
males (mean age—22 ± 2 years), who attended the laboratory after an overnight (10 h) fast, using the
Bergstrom percutaneous needle technique. Samples were blotted free of excess blood and dissected
free of any fat or connective tissue before being placed in OCT compound and frozen in liquid
nitrogen-cooled isopentane. Muscle samples were then stored at −80 ◦C until further analysis. Muscle
samples for Western blot were collected after an overnight fast and 15 min after an acute bout of exercise,
as previously described [27]. Samples (200–300 mg) were immediately processed for sarcolemmal
vesicles and cytosolic fractions, as previously described [28], before being stored at −80 ◦C until
further analysis.
2.3. Immunofluorescent Staining
Embedded muscle samples were fixed in front of the microtome blade (Bright 5040, Bright
Instrument Company Limited, Huntingdon, UK) and cryo-sections (5 µm) collected onto room
temperature uncoated glass slides (VWR International, Lutterworth, UK). Sections were left to air dry
at room temperature for 10 min to remove excess crystallized water inside sections under storage.
Sections were fixed in acetone and ethanol (3:1) solution (Fisher, Loughborough, UK) for 5 min and
then washed for 3 × 5 min in phosphate buffered saline (PBS) supplemented with 0.2% Tween (PBS-T)
to remove fixation reagent. Sections were then incubated in primary antibody solution diluted with
5% normal goat serum (Invitrogen, Loughborough, UK) for 2 h at room temperature. For blocking
peptide experiments, the anti-SLC7A5 antibody was pre-incubated with its corresponding peptide
(20 times greater than primary antibody concentration) on an orbital shaker for 1 h at room temperature.
Following incubation, sections were washed for 3 × 5 min in PBS-T and incubated in the appropriate
secondary antibody for 1 h at room temperature. If needed, sections were finally incubated with Wheat
Germ Agglutinin (WGA-350) for 30 min at room temperature to mark the sarcolemmal membrane.
After a final wash in PBS, slides were left to air dry until the visual water stains evaporated: 1–2 min
at room temperature. Sections were mounted with 20 µL Mowiol® 4-88 (Sigma-Aldrich, Gillingham,
UK) and sealed by glass coverslips to protect the muscle sections and to preserve fluorescence signals.
Slides were left overnight in a dark room before observation. Primary antibodies, blocking peptides
and corresponding secondary antibodies and working dilutions are listed in Table 1. All secondary
antibodies were sourced from ThermoFisher Scientific Inc. (Waltham, MA, USA).
Table 1. Summary of antibodies used.
Primary Antibody Source Dilution Secondary Antibody Dilution
Rabbit polyclonal anti-Solute Carrier
family 7 member 5 (SLC7A5)
antibody isotype IgG
Abcam, ab85226 1:100 Goat anti-rabbitIgG(H+L) Alexa®488 1:200
SLC7A5 peptide Abcam, ab192836 1:10 N/A N/A
Mouse monoclonal anti-Dystrophin
antibody, isotype IgG2a
DSHB, MANDYS1
3B7 1:200
Goat anti-mouse IgG2a
Alexa®594 1:200
Mouse monoclonal anti-Myosin
Heavy Chain 1 (MHC1) antibody,
isotype IgM
DSHB, A4.480 1:500 Goat anti-mouse IgMAlexa®594 1:200
Mouse monoclonal anti-endothelial
nitrate oxide synthase (eNOS)
antibody, isotype IgG1
BD Transduction,
#610297 1:200
Goat anti-mouse IgG1
Alexa®594 1:200
Wheat Germ Agglutinin-350 W11263, Invitrogen 1:20 Alexa Fluor
® 350
Conjugated
N/A
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2.4. Image Capture
Prepared slides were observed under a Nikon E600 widefield microscope using a
40 × 0.75 numerical aperture objective. Images per area were captured under three colour
filters achieved by a SPOT RT KE colour three shot CCD camera (Diagnostic Instruments Inc.,
Sterling Heights, MI, USA), illuminated by a 170 W Xenon light source. For image capture,
4′,6-diamidino-2-phenylindole (DAPI) UV (340–380 nm) filter was used to view WGA-350 (blue) signals
and LAT1 stains tagged with Alexa 488 fluorophores (green) were visualised under the Fluorescein
isothiocyanate (FITC) (465–495 nm) excitation filter. The Texas-Red (540–580 nm) excitation filter was
used to capture signals of eNOS (blood vessels), dystrophin (sarcolemma) or Myosin heavy chain
1 (Type I Fibres), which were conjugated with Alexa Fluor 594 fluorophores. On average, 8 images
were captured per section, and each image contained ~8 muscle fibres. As 2 sections per participant
were imaged, approximately 120 fibres per subject were used for analysis. Image processing and
analysis was undertaken on ImagePro Plus 5.1 (Media Cybernetics, Rockville, MD, USA) and all
factors, i.e., exposure time and gain, were kept constant between all images on each individual slide.
All images underwent flattening and de-speckling prior to quantification of co-localization to limit the
contribution of background, non-specific fluorescence. Image signals generated by WGA or dystrophin
were used to estimate cell membrane borders, and MHC1 staining was utilised to identify type I fibres.
The intensity of LAT1 staining in these groups of fibres was used to assess any differences in fibre type
abundance of the LAT1 protein.
2.5. Immunoblotting
As a qualitative methodological comparator with immunofluorescence for the spatial distribution
of LAT1, giant sarcolemmal vesicles were isolated from the vastus lateralis of a subset healthy
males (n = 2, ~21 years of age) as previously described [29]. The protein pellets that remained
were resuspended and homogenized in a buffer containing 3-(N-morpholino)propanesulfonic acid
(MOPS) (10 mM), KCl (140 mM), Ethylenediaminetetraacetic acid (EDTA) (10 mM), and protease
inhibitors. Samples were centrifuged at 800× g 10 min at 4 ◦C to remove insoluble proteins. Protein
concentrations in cytosolic and sarcolemmal vesicle fractions were determined by BCA assay and
prepared at equal concentrations in 4× Laemmli buffer. In addition, 3 µg of protein were loaded on
a precast gel (BioRad 5671094), run at 200 V for 45 min, transferred (100 V for 1 h) to nitrocellulose
membrane, stained with Ponceau S solution, blocked in 5% skim milk, and probed overnight (1:1000 in
Tris-buffered saline, supplemented with 0.1% Tween (TBST)) using the same anti-LAT1 antibody used
for immuno-fluorescent staining (see Table 1). The membrane was incubated in goat anti-rabbit IgG
Horseradish peroxidase (HRP) conjugated secondary (Thermo Fisher, cat. 31460; 1:10,000 in TBST) for
1 h at RT before washing in TBST and detection by chemiluminescence. Images were captured using a
Fluorochem E Imaging system (Protein Simple; Alpha Innotech, Santa Clara, CA, USA).
2.6. Statistical Analysis
All statistical analysis was conducted on SPSS version 22 for Windows (SPSS Inc.,
Chicago, IL, USA). Differences between the staining intensity in type I and type II fibres was analysed
by a paired-samples t-test. Significance threshold was set at p ≤ 0.05. Data are presented as Mean ± SE
unless otherwise stated.
3. Results
3.1. Characterisation and Validation of LAT1 Immunofluorescence Labelling Approaches
In WT skeletal muscle samples, positive LAT1 signals were noted at the periphery of many fibres,
in addition to displaying a stronger sarcoplasmic staining than seen in mKO samples (Figure 1A).
In mKO samples, positive LAT1 staining was almost completely abolished (Figure 1B). We take this
data to suggest that the anti-LAT1 antibody utilised here is specific to the LAT1 protein in skeletal
Nutrients 2018, 10, 23 5 of 14
muscle, This was further confirmed, as the pattern of staining noted in mKO samples was similar to
that seen when the primary antibody was omitted from staining protocols.
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2C), further confirming the antibody’s specificity to the LAT1 protein. The immunoblot data also 
demonstrate the presence of LAT1 in the sarcolemma and cytosolic protein fractions (Figure 2D). 
Figure 1. I munofluore etection of L-Type amino acid transporter 1 (LAT1) in wild type (WT)
and LAT1 uscle-specific knockout (mKO) mouse extensor digitorum longus (EDL) muscle. Sections
were stained with anti-LAT1 antibody (far left panels, green) and then co-stained with dystrophin
(middle panels, red) for the identification of the sarcolemma. Representative images for both WT (A)
and mKO (B) are shown. Scale bar in top left panel is 50 µm and all images were captured at the
same magnification.
Next, we applied the same staining technique to human skeletal muscle (Figure 2A,B). Here,
a similar staining pattern was noted, with positive-LAT1 puncta close to the sarcolemmal membrane
(dystrophin positive staining). Additionally, a possible fibre-type difference in LAT1 content was
apparent in human tissue. Finally, when the anti-LAT1 antibody was incubated with a LAT1-specific
blocking peptide, the immunofluorescent signal and staining pattern was greatly reduced (Figure 2C),
further confirming the antibody’s specificity to the LAT1 protein. The immunoblot data also
demonstrate the presence of LAT1 in the sarcolemma and cytosolic protein fractions (Fig re 2D).
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Figure 3C). This results suggests that a greater amount of LAT1 is expressed in more glycolytic 
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sarcoplasm as positive LAT1 staining is still apparent at the sarcolemma of type I fibres (Figure 
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Figure 2. Immunofluorescent detection of LAT1 in human vastus lateralis muscle. Sections were
stained with anti-LAT1 antibody (far left panels, green) and then co-stained with dystrophin (middle
panels, red) for the identification of the sarcolemma. Representative images from two participants are
displayed (A,B). Use of a peptide competition assay reduced the signal intensity of LAT1 staining (C).
A strong positive signal was noted close to the sarcolemmal membrane and possible sites of blood
vessels. In addition, a possible fibre type difference in LAT1 staining was noted. Immunoblots for the
LAT1 protein displayed bands to be apparent in both giant sarcolemmal vesicles and cytosolic fractions
before (PRE) and after (POST) an acute bout of resistance exercise (D) (n = 2). Scale bar in top left panel
is 50 µm and all images were captured at the same magnification.
3.2. LAT1 Protein Content Is Greater in Fast-Twitch Skeletal Muscle Fibres
To examine fibre type distribution, LAT1 was co-stained with myosin heavy-chain 1 (MHC1)
to identify type I fibres. This allowed us to quantify LAT1 positive staining in type I and II fibres.
Representative images of this stain (Figure 3A,B) displayed a difference in LAT1 staining between
fibre types with a greater staining intensity seemingly apparent in type II fibres. Quantification of the
staining intensity in each fibre type (Figure 3C) confirmed this as an 82.7% greater staining intensity
was noted in type II fibres compared to type I fibres (25.07 ± 5.93 vs. 13.71 ± 1.98, p < 0.01, Figure 3C).
This results suggests that a greater amount of LAT1 is expressed in more glycolytic fibres, which do not
express MHC1; however, it seems the difference predominantly occurs in the sarcoplasm as positive
LAT1 staining is still apparent at the sarcolemma of type I fibres (Figure 3A,B).
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of the sarc lemma and MHC1 (mi dle panels, red s rcoplasmic staining, marked with I) for the
identification of type I muscle fibres. Representative imag s from two participants are displayed (A,B).
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staining in typ II fibres (C). O average, 103 ± 17 fibres were quantified pe participant. Values are
Mean ± SE *, significantly different to type I (p < 0.01). The scale bar in the top left pan l is 50 µm and
all im g s were captured at the sam magnification.
3.3. L T1 Localises lose to the icrovasculature
To assess L T1 interaction ith the icrovasculature, L T1 as co-stained ith anti-e S
antibody, in order to identify blood vessels. This antibody has previously been utilised in hu an
skeletal uscle to positively stain capillaries and other micro-vessels [30]. Here, it was apparent that
positive LAT1 staining occurred close to positive staining of the microvasculature (eNOS), as shown
in the merged and zoomed images (Figure 4, bottom panels), suggesting that LAT1 localises close to
skeletal muscle vasculature at rest.
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Figure 4. Immunofluorescent detection of LAT1 in human vastus lateralis muscle co-stained with
endothelial nitric oxide synthase (eNOS) and Wheat Germ Agglutinin (WGA). Sections were stained
with anti-LAT1 antibody (green) and then co-stained with eNOS (red) for the identification of blood
vessels. WGA (blue) was used to identify membrane borders. Representative images from two
participants are displayed. Merged images display positive LAT1 staining localising close to positive
eNOS staining, shown in greater detail in zoomed images (bottom panels). Scale bar in top left panel is
50 µm and all images (except zoomed images) were captured at the same magnification. Scale bar in
bottom panels is 5 µm.
4. Discussion
LAT1/SLC7A5 is a transmembrane amino-acid transporter, which imports leucine and other
BCAAs into cells in exchange for glutamine. This places LAT1 as a central regulator of skeletal muscle
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protein dynamics given the importance of leucine in activating mTORC1 and initiating MPS after
feeding [31]. Previous studies investigating LAT1 in human skeletal muscle have focussed on gene
expression and protein levels of this transporter in whole muscle homogenates, measures that do not
provide much information about LAT1 physiological function as the LAT1 protein is only ‘active’ when
associated with cellular membranes [9]. Therefore, in this study, we aimed to validate and optimise
an immunofluorescence staining method to visualise LAT1 in human skeletal muscle. Using this
approach, we observed LAT1 to be in two pools within in basal human skeletal muscle: within the
sarcoplasm and associated with the sarcolemma. Furthermore, we report novel information showing
LAT1 to be expressed in a fibre-specific manner and located in close proximity to the microvasculature.
Staining for LAT1 in fasted human skeletal muscle tissue displayed a strong immunoreactivity
close to the sarcolemmal membrane (Figure 2), which was confirmed by its presence within a
giant sarcolemmal vesicle preparation (Figure 2D). This fraction, which is primarily sarcolemmal
membrane but may also contain recycling endosomal membranes [32], has been previously shown
to contain intracellular fat (e.g., FAT/CD36) and glucose transporters (e.g., GLUT4) in rodent and
human muscle [28,33]. This primary location of LAT1-positive staining along the sarcolemmal
membrane is in congruence with its purported role as a transceptor [34]. As the primary transporter of
BCAAs into muscle cells [19], fully functioning LAT1 would need to associate with the sarcolemmal
membrane in order to convey free amino acids into muscle fibres [35]. Structurally, LAT1, a permease,
can associate with a glycoprotein, CD98 (SLC3A2) [35,36], to form a heterodimer at a membrane.
This association tethers LAT1 to the membrane, allowing the permease to transport amino acids across
the membrane [36,37]. Furthermore, any role as a sensor of extracellular amino acids would also
require LAT1 to be associated with the sarcolemma, as either a transporter or a signalling molecule
LAT1 would have to associate with the membrane [8,34]. Although our data is the first study to utilise
immunofluorescence staining techniques to detect LAT1 in human skeletal muscle, this protein has
previously been visualised in other tissues. In human placenta, LAT1 was visualised predominantly
at the microvillous membrane of terminal villi and was essential for leucine uptake into placenta
cells [38]. Furthermore, LAT1 is located in plasma membranes of Laryngeal Squamous tumours [39],
where amino acid uptake is elevated to provide substrates for tumour growth [40]. Several other tissues
also express LAT1 principally in membranous structures including foetal intestines [41], non-small cell
lung carcinomas [42] and ovarian tumours [43]. This consistent visualisation of LAT1 at membranes
of tissues where protein synthesis/cell division is high consolidates our findings in human skeletal
muscle, a tissue in which a regular supply of EAAs is imperative for optimal cell function and
turnover [2].
Skeletal muscle is perfused by an intricate network of capillaries, and other microvessels,
providing the working tissue with adequate supplies of oxygen and substrates whilst simultaneously
removing waste products. Essential amino acids are transported to the muscle via this network,
entering the bloodstream via absorption in the small intestine after food is consumed [44]. As this
is the most ready supply of essential amino acids for skeletal muscle (other than intracellular amino
acid recycling from protein breakdown), we investigated whether LAT1 would localise close to blood
vessels. We display strong LAT1 immunoreactivity with eNOS. Such close association between an area
of high supply (bloodstream) and one of high demand (skeletal muscle) suggests a high efficiency of
amino acid transport in human skeletal muscle. Similar localisations have been displayed in other
tissues with high LAT1 expression noted at blood–brain barriers in rodents [45,46] and chickens [47].
Additionally, other amino acid transporters are also seen in these regions [47], further implying a high
efficiency of amino acid transport at blood–tissue junctions.
When staining for the LAT1 protein in skeletal muscle, a difference in the intensity of LAT1
staining between some fibres was apparent. We hypothesised that this may be specific to a particular
fibre type and confirmed this by co-staining LAT1 with an anti-MHC1 antibody to identify type I
(oxidative) fibres (Figure 3). LAT1 expression was greater in type II fibres and this seemed to be
driven by a greater staining intensity within the sarcoplasm of these fibres, suggesting a greater
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dynamic pool in these fibres. This was confirmed via immunoblotting of mixed human skeletal
muscle giant sarcolemmal vesicles and cytoplasmic fractions (Figure 2D), the latter of which may
include membranes associated with sorting endosomes, lysosomes, and intracellular organelles
(e.g., endoplasmic reticulum, Golgi apparatus) that would be distinct from those extracted in the
giant sarcolemmal vesicles [32,48]. Immunoblotting displayed expression of the LAT1 protein in
both fractions adding further validation to our observations of greater LAT1 staining intensity
in the sarcoplasm of type II fibres. Several mechanisms within skeletal muscle may explain this
apparent increase in sarcoplasmic LAT1 within more glycolytic fibres. Firstly, increases in LAT1
protein could result from mTORC1 activation. In response to essential amino acid ingestion [12],
resistance exercise [11], or both in combination [10,49], stimuli that have been consistently reported to
transiently activate mTORC1, LAT1 gene expression and protein levels are elevated in young and old
males. In addition, alterations in LAT1 gene expression and protein levels following platelet-derived
growth factor incubation are abolished by co-incubation with rapamycin [24], an mTORC1 inhibitor.
As type II fibres show a greater elevation in mTORC1 activity in response to exercise [50], it is
possible that this drives greater transcription/translation of LAT1 in these fibres, which remains
apparent in fasted tissue. It may also be possible that, due to the greater levels of mTORC1 activity
experienced in these fibres, LAT1 is required in the membrane of intracellular lysosomes as shown
in some in vitro models [51]. Here, LAT1 could maintain intralysosomal amino acid concentrations,
which are believed to then contribute to mTORC1 activation [52]. It is also possible that sarcoplasmic
LAT1 may translocate toward the sarcolemmal membrane in response to stimuli where an increase in
amino acid transport occurs (i.e., mechanical stimulation or feeding [20]). In fact, the translocation
capacity of LAT1 has been previously reported in BeWo Chariocarcinoma cells after exposure to
IGF-1, where the transporter translocated from perinuclear regions toward the cell membrane [53].
An increase in membrane-associated LAT1 protein will then increase the amount of amino acids that
can be transported into the cell for protein synthesis/repair. Since we show a greater intracellular
concentration of LAT1 in type II fibres, if LAT1 does translocate, this would suggest that type II
fibres would have the greatest anabolic potential. It is important that this fibre-type difference in
LAT1 expression is further investigated to fully understand the underpinning mechanisms and how
signalling/metabolism in these fibres are affected.
5. Conclusions
To conclude, we have validated and optimised a method by which LAT1 can be visualised
in human skeletal muscle. As this amino acid transporter is only active when associated with
cellular membranes, this novel method allows a greater depth of investigation into the dynamics
of LAT1 in human muscle in response to anabolic stimuli. For the first time, we have identified
LAT1 to be primarily located close to the plasma membrane of all fibres and in close proximity to the
microvasculature. Furthermore, we note a greater immunoreactivity of this protein in the sarcoplasm
of type II fibres, potentially supporting the greater anabolic potential in these fibres. We believe this
technique may provide a valuable insight into the role of LAT1 in skeletal muscle amino acid sensing,
intracellular signalling, and subsequently adaptation. It is important to acknowledge, however,
that the use of immunofluorescence microscopy as discussed here can only infer localization of target
proteins. To gain greater insight into whether the LAT1 protein is directly localized to the sarcolemmal
membrane, microvasculature or actin myosin bundles, immune-electron microscopy could be utilized
and/or isolation of giant sarcolemmal vesicles. However, the present immunofluorescence technique
requires less tissue (i.e., ~20 mg vs. >200 mg) than isolated giant sarcolemmal vesicles and can be
characterized from frozen as compared to fresh samples, which represent significant advantages when
muscle tissue samples are limited. Future research should now focus on identifying the possible
underlying mechanisms, and consequences, of the fibre type differences reported here. Moreover,
investigations into how factors such as ageing, exercise and feeding regulate LAT1 cellular location
should also be undertaken. As LAT1 is the principal mechanism by which leucine enters the cell,
Nutrients 2018, 10, 23 11 of 14
approaches to increase LAT1 content or activity in skeletal muscle could have substantial relevance to
post-exercise recovery strategies in which dietary protein or amino acids are of direct importance.
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